UK based developer gains investment for world’s first portable fingerprint drug test

UK-based Intelligent Fingerprinting, have secured £1.7 million of funding from a group of private US and UK investors for the world’s first portable fingerprint drug test. The investment will allow for accelerated commercialisation of the recently launched Intelligent Fingerprinting Drug Screening System. Particularly into key UK workplace market sectors such as construction, transport, warehousing and

Continue Reading

Gene therapy medication, Spinraza, provides improvements for patients with spinal muscular atrophy

Spinraza has provided significant improvements in cases with the next most severe form of the neuromuscular disease, spinal muscular atrophy (SMA), which affects children aged from 6 to 18 months.   “The effects are convincing, and this reinforces results from the earlier study,” says Mar Tulinius, Professor of paediatrics at Sahlgrenska Academy and chief medical

Continue Reading

Bicycle and CRUK to launch first clinical trial of bicyclic peptide for use in treating tumours

Bicycle Therapeutics and Cancer Research UK have commenced the first clinical study to assess a bicyclic peptide to evaluate its potential in patients with advanced solid tumours. The first patient has now been dosed in a Phase I/IIa trial with BT1718, a first-in-class Bicycle Toxin Conjugate that targets Membrane Type 1 Matrix Metalloproteinase, which is

Continue Reading

New cancer blood test breakthrough

Scientists from Johns Hopkins University have taken a step towards one of the biggest goals in medicine, a universal blood test for cancer. The researchers have trialled a method that can detect up to eight common forms of the disease. The scientists envision the research to be developed into an annual test designed to catch

Continue Reading

CRUK and Institute of Cancer Research, London collaborate with Merck in new drug discovery alliance

Cancer Research UK’s Commercial Partnerships Team and The Institute of Cancer Research, announced a multi-project collaboration and licensing deal with Merck, a leading science and technology company, to discover and develop new anticancer drugs. “It is an exciting example of how successful academic networks and the scale of industry can combine to advance scientific and

Continue Reading